A pharmacoepidemiologic study of trandolapril

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 9, 1997, Pages 555-563

  Jouglard, Jacqueline ^a   Hamel, Jean Dominique ^b   Juvin, Philippe ^b  

^a Child and Adolescent Psychopathology Unit Salvator Hospital Public Assistance Marseille Hospitals University Aix Marseille II   (France)

^b Laboratoires Knoll France   (France)

Author keywords

Cohort study; Pharmacoepidemiology; Pharmacovigilance; Postmarketing surveillance; Trandolapril

Indexed keywords

FUROSEMIDE; TRANDOLAPRIL;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; ASTHENIA; CLINICAL TRIAL; COUGHING; DEATH; DRUG MONITORING; ETHNOLOGY; FEMALE; FLUSHING; FRANCE; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; KIDNEY FAILURE; LARYNGITIS; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MYALGIA; NAUSEA; ORTHOSTATIC HYPOTENSION; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; RASH; RHINITIS; RHINORRHEA; SEX DIFFERENCE; SLEEP DISORDER; URTICARIA; VERTIGO;

EID: 0030870830     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80081-1     Document Type: Article

References (29)

1. Ferner RB. Newly licensed drugs. BMJ. 1996;313:1157-1158.
2. Rawlins MD. Postmarketing surveillance of adverse reactions to drugs. BMJ. 1984;288: 879-880.
3. Langman MJS. Did the drug do it? BMJ. 1986;293:219-220.
4. Edwards R. Competing in drug safety. Lancet. 1992;342:631-632.
5. Zaumad F. Trandolapril - How does it differ from other angiotensin converting enzyme inhibitors? Drugs. 1993;46(Suppl 2):172-182.
6. Wiseman LR, McTavish D. Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs. 1994;48:71-90.
7. N'Guyen Cong Duc L, Brunner HR. Trandolapril in hypertension: Overview of a new angiotensin-converting enzyme inhibitor. Am J Cardiol. 1992;70(Suppl):27-34.
8. Backhouse CI, Orofiamma B, Pauly NC. Long term therapy with trandolapril, a new nonsulfhydryl ACE inhibitor, in hypertension: A multicenter international trial. J Cardiovasc Pharmacol. 1994;23(Suppl 4):S86-S90.
9. COSTART (Coding Symbols for Thesaurus of Adverse Reaction Terms). 3rd ed. Washington, DC: Food and Drug Administration; 1989.
10. Begaud B, Evreux JC, Jouglard J, Lagier G. Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France. Therapie. 1985; 40:111-118.
11. Shaw J. On the Inhalation of Vapour of Ether in Surgical Operation. London: John Churchill, 1847.
12. Haramburu F, Begaud B, Péré JC. Comparison of 500 spontaneous and 500 published reports of adverse drug reactions. Eur J Clin Pharmacol. 1990;39:287-288.
13. Rossi AC, Knapp DE, Anello C, et al. Discovery of adverse drug reactions - a comparison of selected phase IV studies with spontaneous reporting method. JAMA. 1983;249:2226-2228.
14. Waller PC, Wood SM, Langman MJS, et al. Review of company postmarketing surveillance studies. BMJ. 1992;304:1470-1472.
15. Fennerty A, Littley M, Reid P. Enalapril-induced nasal blockage. Lancet. 1986;2:1395-1396.
16. Balduf M, Steinkraus V, Ring J. Captopril associated lacrimation and rhinorrhoea. BMJ. 1992;305:693. Letter.
17. Haramburu F, Chaslerie A, Begaud B. Inhibiteurs de l'enzyme de conversion et toux. Le Concours Médical. 1995;117:586-588.
18. Israili ZI, Dallas Hall W. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med. 1992;117:234-242.
19. Yeo WW, Foster G, Ramsay LE. Prevalence of persistent cough during long term enalapril treatment: Controlled study versus nifedapine. Q J Med. 1991;293:763-770.
20. Yeo WW, Ramsay LE. Persistent dry cough with enalapril: Incidence depends on method used. J Hum Hypertens. 1990;4:517-520.
21. Frank GJ, Knapp LE, McLain RW. Overall tolerance and safety of quinapril in clinical trials. Angiology. 1989;40:405-415.
22. Materson BJ. Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril. Am J Cardiol. 1992;69(Suppl 3):46C-53C.
23. Singer DKJ, MacGregor GA. Angioneurotic oedema associated with two angiotensin converting enzyme inhibitors. BMJ. 1986;293:1243. Letter.
24. Jett GK. Captopril-induced angioedema. Ann Emerg Med. 1984;13:489-490.
25. Burkhart GA, Brown NJ, Griffin MR, et al. Angiotensin converting enzyme inhibitor-associated angioedema: Higher risk in blacks and whites. BMJ. 1996;5:149-154.
26. Chalmers D, Whitehead A, Lawson DH. Post-marketing surveillance of captopril for hypertension. Br J Clin Pharmacol. 1992;43:215-223.
27. Rosenthal JR, Osowski U. Tolerability and efficacy of antihypertensive treatment with cilazapril in general practice. Cardiology. 1996;87:54-59.
28. Jaillon P, Vicaut E, Caffe S, Dallocchio M. Pharmaco-epidemiology of quinapril in hypertensive patients followed for 6 months. J Cardiovasc Pharmacol. 1992;20(Suppl B):S39-S44.
29. Fressinaud P, Berrut G, Gallois H. Activité antihypertensive, acceptabilité clinique et biologique due perindopril: Principaux résultats chez 23640 hypertendus légers à modérés traités pendant 6 mois en médecine générale. Ann Cardiol Angeiol (Paris). 1993;42:51-59.